Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy.
Dieci MV, Griguolo G, Bottosso M, Tsvetkova V, Giorgi CA, Vernaci G, Michieletto S, Angelini S, Marchet A, Tasca G, Genovesi E, Cumerlato E, Lo Mele M, Conte P, Guarneri V. Dieci MV, et al. Among authors: cumerlato e. NPJ Breast Cancer. 2021 Aug 2;7(1):101. doi: 10.1038/s41523-021-00308-7. NPJ Breast Cancer. 2021. PMID: 34341356 Free PMC article.
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V. Miglietta F, et al. Among authors: cumerlato e. Oncologist. 2020 Sep;25(9):e1355-e1362. doi: 10.1634/theoncologist.2020-0201. Epub 2020 Jul 21. Oncologist. 2020. PMID: 32618068 Free PMC article.
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Tasca G, Giorgi CA, Cumerlato E, Massa D, Lo Mele M, Orvieto E, Guarneri V, Conte P. Dieci MV, et al. Among authors: cumerlato e. Eur J Cancer. 2020 Sep;136:7-15. doi: 10.1016/j.ejca.2020.05.014. Epub 2020 Jul 1. Eur J Cancer. 2020. PMID: 32622323 Free article.
Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease.
Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Mantiero M, Tasca G, Cumerlato E, Giorgi CA, Giarratano T, Faggioni G, Falci C, Vernaci G, Menichetti A, Mioranza E, Di Liso E, Frezzini S, Saibene T, Orvieto E, Guarneri V. Dieci MV, et al. Among authors: cumerlato e. Front Oncol. 2019 Jun 6;9:452. doi: 10.3389/fonc.2019.00452. eCollection 2019. Front Oncol. 2019. PMID: 31245286 Free PMC article.
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study.
Di Liso E, Menichetti A, Dieci MV, Ghiotto C, Banzato A, Bianchi A, Pintacuda G, Padovan M, Nappo F, Cumerlato E, Miglietta F, Mioranza E, Zago G, Corti L, Guarneri V, Conte P. Di Liso E, et al. Among authors: cumerlato e. J Palliat Med. 2019 Jun;22(6):691-695. doi: 10.1089/jpm.2018.0491. Epub 2019 Mar 19. J Palliat Med. 2019. PMID: 30888908
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Pasello G, Lorenzi M, Scattolin D, Del Conte A, Cecere F, Pavan A, Macerelli M, Polo V, Pilotto S, Santarpia M, Cumerlato E, Da Ros V, Targato G, Bortolami A, Bonanno L, Ferro A, Dal Maso A, Frega S, Guarneri V. Pasello G, et al. Among authors: cumerlato e. Oncologist. 2024 Mar 23:oyae043. doi: 10.1093/oncolo/oyae043. Online ahead of print. Oncologist. 2024. PMID: 38520745 Free article.
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
Dieci MV, Carbognin L, Miglietta F, Canino F, Giorgi CA, Cumerlato E, Amato O, Massa D, Griguolo G, Genovesi E, Garufi G, Giannarelli D, Tornincasa A, Trudu L, Michieletto S, Saibene T, Lo Mele M, Fassan M, Zarrilli G, Piacentini F, Bria E, Guarneri V. Dieci MV, et al. Among authors: cumerlato e. Br J Cancer. 2023 Jan;128(2):398. doi: 10.1038/s41416-022-02087-9. Br J Cancer. 2023. PMID: 36460777 Free PMC article. No abstract available.
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation.
Dieci MV, Carbognin L, Miglietta F, Canino F, Giorgi CA, Cumerlato E, Amato O, Massa D, Griguolo G, Genovesi E, Garufi G, Giannarelli D, Tornincasa A, Trudu L, Michieletto S, Saibene T, Lo Mele M, Fassan M, Zarrilli G, Piacentini F, Bria E, Guarneri V. Dieci MV, et al. Among authors: cumerlato e. Br J Cancer. 2023 Jan;128(2):266-274. doi: 10.1038/s41416-022-02050-8. Epub 2022 Nov 17. Br J Cancer. 2023. PMID: 36396818 Free PMC article.